Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
RenovoRx Announces Clinical Data Supporting the TAMP Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
American Uranium Expands its Lo Herma ISR Uranium Project in Wyoming's Powder River Basin as Company Secures Strategically Located Uranium Mineral Rights and Stakes Additional Mining Claims
